Developer docs
API playgroundTry for free, no card

Search company profiles

Curis

Full company profile

uuid0003g3x

Namestring
Curis
Legal namestring
Curis, Inc.
Websiteurl
curis.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Curis, Inc. is a clinical-stage biotechnology company headquartered in Lexington, Massachusetts, founded in 2000 and publicly traded on NASDAQ under ticker CRIS. The company's core focus is the development of emavusertib (CA-4948), an orally available small molecule that inhibits both IRAK4 and FLT3, enabling dual blockade of NF-kB through the TLR and BCR pathways. Emavusertib is being evaluated in Phase 1/2 and Phase 2 clinical trials across hematologic malignancies including primary and secondary CNS lymphoma (TakeAim Lymphoma study), chronic lymphocytic leukemia (TakeAim CLL), and acute myeloid leukemia and myelodysplastic syndromes (TakeAim Leukemia study), with key clinical collaborations at Dana-Farber Cancer Institute, Mayo Clinic, and IRCCS Bologna. The asset has received FDA Orphan Drug Designation for PCNSL, AML, and MDS, plus European Commission Orphan Drug Designation for PCNSL. The pipeline also includes Fimepinostat (HDAC/PI3K inhibitor for MYC-altered cancers), CA-327 (TIM3/PDL1 inhibitor), and CA-170 (VISTA/PDL1 inhibitor), with emavusertib licensed exclusively from Aurigene Discovery Technologies via a 2015 collaboration.

The company's revenue model has historically been driven by royalty payments from Genentech and Roche's net sales of Erivedge (vismodegib), a hedgehog pathway inhibitor originally developed by Curis. However, in November 2025 Curis sold its Erivedge royalty interest and associated intellectual property to TPC Investments Royalty LLC for $2.5 million upfront, eliminating this revenue stream. FY2025 reported revenue was $9.4 million (down from $10.9M in FY2024), all royalty-derived and now discontinued. The company has no commercial products and does not yet generate product revenue, with commercialization dependent on regulatory approval and likely executed via pharmaceutical partnership or internal specialty oncology build-out. Operating geographies are concentrated in the United States, with clinical trial expansion into Europe. The company employs 11-50 people and is funded through repeated dilutive financings, most recently a January 2026 PIPE of up to $80.8 million led by Laidlaw & Company, extending cash runway into the second half of 2027.

Short descriptiontext

Curis is a clinical-stage biotechnology company developing emavusertib (CA-4948), an IRAK4/FLT3 inhibitor in Phase 1/2 and Phase 2 trials for hematologic malignancies including PCNSL, CLL, and AML, with FDA and EMA Orphan Drug Designations and exclusive licensing from Aurigene Discovery Technologies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, small molecule therapeutics, kinase inhibitor research, hematologic cancer treatments, clinical stage biopharmaceuticals
Industry1 code
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Erivedge Royalties (Discontinued)
TypeLicensing Royalties
Description

Curis historically received royalty revenues from Genentech and Roche's net sales of Erivedge. On November 6, 2025, the company sold its interest in Curis Royalty LLC, including the Erivedge intellectual property and License Agreement with Genentech, to TPC Investments Royalty LLC for $2.5 million upfront consideration. Following this sale, the company is no longer entitled to revenues under the License Agreement, eliminating this revenue stream going forward.

investors.curis.com
2Private Placement Financing
TypeLicensing Royalties
Description

Company raised gross proceeds of up to $80.8 million through private placement financing involving Series B convertible preferred stock and warrants to fund research and development of emavusertib and general corporate expenses.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Emavusertib (CA-4948)
Description

Orally available small molecule IRAK4 and FLT3 inhibitor being developed for the treatment of hematologic malignancies including lymphoma, CLL, and AML.

curis.com
+3 more records
Core offering1 text field

Curis is a clinical-stage biotechnology company developing orally available small molecule cancer therapeutics, with its lead candidate emavusertib (CA-4948), an IRAK4 and FLT3 inhibitor, being evaluated in Phase 1/2 and Phase 2 clinical studies for the treatment of primary CNS lymphoma (PCNSL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). The company also has pipeline candidates fimepinostat, CA-327, and CA-170 targeting other hematologic and immune checkpoint pathways. Historically, Curis generated royalty revenue from Genentech and Roche's sales of Erivedge; that royalty interest was divested to TPC Investments Royalty LLC in November 2025.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% objective response rate (5 of 5 patients) in BTKi-naïve PCNSL patients treated with emavusertib + ibrutinib combination
+3 more records
Product overview1 text field

Curis is a biotechnology company focused on the development of innovative therapeutics for cancer treatment. The company's lead product is emavusertib (CA-4948), an orally available small molecule IRAK4 and FLT3 inhibitor being evaluated in multiple clinical trials for lymphoma (TakeAim Lymphoma), chronic lymphocytic leukemia (TakeAim CLL), and acute myeloid leukemia. The pipeline also includes Fimepinostat (HDAC/PI3K inhibitor for MYC-altered cancers), CA-327 (TIM3/PDL1 inhibitor), and CA-170 (VISTA/PDL1 inhibitor). The company operates through a 2015 collaboration with Aurigene Discovery Technologies Limited for emavusertib licensing rights.

Product and service1 record
1Emavusertib (CA-4948)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

2015 collaboration providing Curis with exclusive license to emavusertib (CA-4948). This is the company's lead drug candidate and core asset. The partnership enables Curis to develop and commercialize the IRAK4 and FLT3 inhibitor for cancer treatment.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Historically, Curis received royalty revenues from Genentech and Roche's net sales of Erivedge. This licensing arrangement ended following the sale of the royalty interest to TPC Investments Royalty LLC in November 2025.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage small molecule oncology company developing tipifarnib (HRAS) and KO-539 (menin inhibitor) for AML and other hematologic malignancies. Directly comparable as a micro/mid-cap biotech with a hematology-focused pipeline of single-agent and combination therapies.

2Rigel Pharmaceuticals
TypeDirect peer
Description

Commercial-stage small molecule company focused on hematologic disorders and cancers (TAVALISSE for ITP, Rezlidhia for AML, Gavreto). Comparable as a small molecule developer with both approved and clinical-stage hematology assets and a similar enterprise scale.

TypeDirect peer
Description

Clinical-stage biotech developing bezuclastinib (KIT D816V inhibitor) for systemic mastocytosis and GIST. Comparable as a small-molecule precision oncology company targeting hematologic malignancies with similar enterprise size and clinical-stage profile.

TypeDirect peer
Description

Clinical-stage oncology company developing small molecules targeting dysregulated transcription (lanifibranor in AML/MDS). Comparable as a small-cap clinical-stage biotech focused on hematologic cancer targets and combination regimens.

TypeEmerging player
Description

Clinical-stage biotech developing targeted protein degraders (including IRAK4 degraders) for oncology and immunology. Comparable technology overlap on IRAK4 modulation for hematologic cancers and similar small-cap clinical-stage profile.

TypeBroad incumbent
Description

Major oncology company marketing Calquence (acalabrutinib BTKi) and with active IRAK4 research programs. Comparable as a broad incumbent in the BTKi/IRAK4 hematology space and a likely potential partner or acquirer for Curis.

TypeBroad incumbent
Description

Global oncology leader marketing Imbruvica (ibrutinib) — the BTKi used in Curis's combination trials — and historically developing IRAK4 inhibitors. Comparable as a strategic partner candidate and dominant player in the BTKi/CLL landscape.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Large oncology company with active IRAK4-targeted programs and a portfolio of hematology therapies. Comparable as a broad incumbent operating in the IRAK4/BTKi space and a potential strategic acquirer.

TypeBroad incumbent
Description

Major oncology company marketing Jaypirca (pirtobrutinib), a next-generation BTKi that competes in Curis's combination setting. Comparable as a broad incumbent in the BTKi/CLL competitive landscape and a relevant benchmark for IRAK4/BTKi combination strategies.

TypeBroad incumbent
Description

Global pharma with historical IRAK4 small molecule programs and a broad hematology/oncology portfolio. Comparable as a broad incumbent in the IRAK4 mechanistic space and a potential strategic acquirer of late-stage hematology assets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curis

Oncology Biopharmaceuticalscuris.com

Curis is a clinical-stage biotechnology company developing emavusertib (CA-4948), an IRAK4/FLT3 inhibitor in Phase 1/2 and Phase 2 trials for hematologic malignancies including PCNSL, CLL, and AML, with FDA and EMA Orphan Drug Designations and exclusive licensing from Aurigene Discovery Technologies.

What Curis does

Curis, Inc. is a clinical-stage biotechnology company headquartered in Lexington, Massachusetts, founded in 2000 and publicly traded on NASDAQ under ticker CRIS. The company's core focus is the development of emavusertib (CA-4948), an orally available small molecule that inhibits both IRAK4 and FLT3, enabling dual blockade of NF-kB through the TLR and BCR pathways. Emavusertib is being evaluated in Phase 1/2 and Phase 2 clinical trials across hematologic malignancies including primary and secondary CNS lymphoma (TakeAim Lymphoma study), chronic lymphocytic leukemia (TakeAim CLL), and acute myeloid leukemia and myelodysplastic syndromes (TakeAim Leukemia study), with key clinical collaborations at Dana-Farber Cancer Institute, Mayo Clinic, and IRCCS Bologna. The asset has received FDA Orphan Drug Designation for PCNSL, AML, and MDS, plus European Commission Orphan Drug Designation for PCNSL. The pipeline also includes Fimepinostat (HDAC/PI3K inhibitor for MYC-altered cancers), CA-327 (TIM3/PDL1 inhibitor), and CA-170 (VISTA/PDL1 inhibitor), with emavusertib licensed exclusively from Aurigene Discovery Technologies via a 2015 collaboration.

The company's revenue model has historically been driven by royalty payments from Genentech and Roche's net sales of Erivedge (vismodegib), a hedgehog pathway inhibitor originally developed by Curis. However, in November 2025 Curis sold its Erivedge royalty interest and associated intellectual property to TPC Investments Royalty LLC for $2.5 million upfront, eliminating this revenue stream. FY2025 reported revenue was $9.4 million (down from $10.9M in FY2024), all royalty-derived and now discontinued. The company has no commercial products and does not yet generate product revenue, with commercialization dependent on regulatory approval and likely executed via pharmaceutical partnership or internal specialty oncology build-out. Operating geographies are concentrated in the United States, with clinical trial expansion into Europe. The company employs 11-50 people and is funded through repeated dilutive financings, most recently a January 2026 PIPE of up to $80.8 million led by Laidlaw & Company, extending cash runway into the second half of 2027.

Curis firmographics

Firmographics
Name
Curis
Legal name
Curis, Inc.
Website
https://curis.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
Curis is a clinical-stage biotechnology company developing emavusertib (CA-4948), an IRAK4/FLT3 inhibitor in Phase 1/2 and Phase 2 trials for hematologic malignancies including PCNSL, CLL, and AML, with FDA and EMA Orphan Drug Designations and exclusive licensing from Aurigene Discovery Technologies.
Ownership category
akta.pro rank

Curis industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Oncology drug development
  • Small molecule therapeutics
  • Kinase inhibitor research
  • Hematologic cancer treatments
  • Clinical stage biopharmaceuticals

Where Curis is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Curis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Erivedge Royalties (Discontinued): Curis historically received royalty revenues from Genentech and Roche's net sales of Erivedge. On November 6, 2025, the company sold its interest in Curis Royalty LLC, including the Erivedge intellectual property and License Agreement with Genentech, to TPC Investments Royalty LLC for $2.5 million upfront consideration. Following this sale, the company is no longer entitled to revenues under the License Agreement, eliminating this revenue stream going forward.
  2. Private Placement Financing: Company raised gross proceeds of up to $80.8 million through private placement financing involving Series B convertible preferred stock and warrants to fund research and development of emavusertib and general corporate expenses.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Curis product offering

Product offering

Core offering

Curis is a clinical-stage biotechnology company developing orally available small molecule cancer therapeutics, with its lead candidate emavusertib (CA-4948), an IRAK4 and FLT3 inhibitor, being evaluated in Phase 1/2 and Phase 2 clinical studies for the treatment of primary CNS lymphoma (PCNSL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). The company also has pipeline candidates fimepinostat, CA-327, and CA-170 targeting other hematologic and immune checkpoint pathways. Historically, Curis generated royalty revenue from Genentech and Roche's sales of Erivedge; that royalty interest was divested to TPC Investments Royalty LLC in November 2025.

Product overview

Curis is a biotechnology company focused on the development of innovative therapeutics for cancer treatment. The company's lead product is emavusertib (CA-4948), an orally available small molecule IRAK4 and FLT3 inhibitor being evaluated in multiple clinical trials for lymphoma (TakeAim Lymphoma), chronic lymphocytic leukemia (TakeAim CLL), and acute myeloid leukemia. The pipeline also includes Fimepinostat (HDAC/PI3K inhibitor for MYC-altered cancers), CA-327 (TIM3/PDL1 inhibitor), and CA-170 (VISTA/PDL1 inhibitor). The company operates through a 2015 collaboration with Aurigene Discovery Technologies Limited for emavusertib licensing rights.

Differentiator

Problem solved

Functional benefit

Brands

  • Emavusertib (CA-4948): Orally available small molecule IRAK4 and FLT3 inhibitor being developed for the treatment of hematologic malignancies including lymphoma, CLL, and AML.
  • Fimepinostat
  • CA-327
  • CA-170

Products and services

  • Emavusertib (CA-4948)

Quantifiable outcome

  • 100% objective response rate (5 of 5 patients) in BTKi-naïve PCNSL patients treated with emavusertib + ibrutinib combination
  • +3 more outcomes

Companies that use Curis

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Curis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Curis partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Aurigene Discovery Technologies LimitedcoreStrategic or Co-development Partner · 1 January 20152015 collaboration providing Curis with exclusive license to emavusertib (CA-4948). This is the company's lead drug candidate and core asset. The partnership enables Curis to develop and commercialize the IRAK4 and FLT3 inhibitor for cancer treatment.
  • Genentech and RocheminorStrategic or Co-development PartnerHistorically, Curis received royalty revenues from Genentech and Roche's net sales of Erivedge. This licensing arrangement ended following the sale of the royalty interest to TPC Investments Royalty LLC in November 2025.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Curis competitors and assessment

Company assessment

Direct peers

  • Kura Oncology: Clinical-stage small molecule oncology company developing tipifarnib (HRAS) and KO-539 (menin inhibitor) for AML and other hematologic malignancies. Directly comparable as a micro/mid-cap biotech with a hematology-focused pipeline of single-agent and combination therapies.
  • Rigel Pharmaceuticals: Commercial-stage small molecule company focused on hematologic disorders and cancers (TAVALISSE for ITP, Rezlidhia for AML, Gavreto). Comparable as a small molecule developer with both approved and clinical-stage hematology assets and a similar enterprise scale.
  • Cogent Biosciences: Clinical-stage biotech developing bezuclastinib (KIT D816V inhibitor) for systemic mastocytosis and GIST. Comparable as a small-molecule precision oncology company targeting hematologic malignancies with similar enterprise size and clinical-stage profile.
  • Kronos Bio: Clinical-stage oncology company developing small molecules targeting dysregulated transcription (lanifibranor in AML/MDS). Comparable as a small-cap clinical-stage biotech focused on hematologic cancer targets and combination regimens.

Emerging players

  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders (including IRAK4 degraders) for oncology and immunology. Comparable technology overlap on IRAK4 modulation for hematologic cancers and similar small-cap clinical-stage profile.

Broad incumbents

  • AstraZeneca: Major oncology company marketing Calquence (acalabrutinib BTKi) and with active IRAK4 research programs. Comparable as a broad incumbent in the BTKi/IRAK4 hematology space and a likely potential partner or acquirer for Curis.
  • AbbVie: Global oncology leader marketing Imbruvica (ibrutinib) — the BTKi used in Curis's combination trials — and historically developing IRAK4 inhibitors. Comparable as a strategic partner candidate and dominant player in the BTKi/CLL landscape.
  • Bristol Myers Squibb: Large oncology company with active IRAK4-targeted programs and a portfolio of hematology therapies. Comparable as a broad incumbent operating in the IRAK4/BTKi space and a potential strategic acquirer.
  • Eli Lilly: Major oncology company marketing Jaypirca (pirtobrutinib), a next-generation BTKi that competes in Curis's combination setting. Comparable as a broad incumbent in the BTKi/CLL competitive landscape and a relevant benchmark for IRAK4/BTKi combination strategies.
  • Pfizer: Global pharma with historical IRAK4 small molecule programs and a broad hematology/oncology portfolio. Comparable as a broad incumbent in the IRAK4 mechanistic space and a potential strategic acquirer of late-stage hematology assets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Curis social profiles

Digital presence

Curis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curis leadership team

Management profile

Number of profiles

Profiles4 records

Curis funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curis

What does Curis do?

Curis is a clinical-stage biotechnology company developing orally available small molecule cancer therapeutics, with its lead candidate emavusertib (CA-4948), an IRAK4 and FLT3 inhibitor, being evaluated in Phase 1/2 and Phase 2 clinical studies for the treatment of primary CNS lymphoma (PCNSL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). The company also has pipeline candidates fimepinostat, CA-327, and CA-170 targeting other hematologic and immune checkpoint pathways. Historically, Curis generated royalty revenue from Genentech and Roche's sales of Erivedge; that royalty interest was divested to TPC Investments Royalty LLC in November 2025.

Is Curis a public or private company?

Curis is a public company. It is classified as public and is currently operating.

When was Curis founded?

Curis was founded in 2000. It employs 101 to 250 people.

Where is Curis based?

Curis is headquartered in Lexington, United States, in the North America region.

How does Curis make money?

Two revenue lines are on record. Erivedge Royalties (Discontinued) is the primary driver. The others are private Placement Financing.

Who are Curis's main competitors?

Direct peers on record are Kura Oncology, Rigel Pharmaceuticals, Cogent Biosciences and Kronos Bio. Kymera Therapeutics is listed as an emerging player. Broad incumbents are AstraZeneca, AbbVie, Bristol Myers Squibb, Eli Lilly and Pfizer.

Does Curis have an API?

No public API is recorded for Curis.

What industry is Curis in?

Curis's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 3254 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHC Wainwright & Co. maintains Curis at Buy, lowers price target to $6 from $43HC Wainwright & Co. maintained Curis at Buy and lowered its price target to $6 from $43, an 86% cut. The target implies an upside of 949.3% from the Nov 12 close of $0.57.Seeking AlphaCuris, Inc. (CRIS) Q3 2026 Earnings Call TranscriptCuris held its Q3 2026 earnings call on November 12, 2026, with CEO Jim Dentzer and CFO Diantha Duvall. Dentzer began discussing progress on the TakeAim Lymphoma study, the company's lead program and first NHL study. The call included forward-looking statements subject to risks and uncertainties.TradingViewCuris Received Notice of DelistingCuris received a Nasdaq delisting determination on November 2, 2026, after its stock closed below $1.00 for 30 consecutive business days. The company, ineligible for a standard compliance period due to a reverse split and Panel Monitor, plans to request a hearing, though no assurance is given that the appeal will succeed.Stock TitanCuris to report Q3 2026 results and host call Nov. 12Curis will report its third quarter 2026 financial and operating results on November 12, 2026, at 4:00 p.m. ET. The company will also host a conference call and webcast on that date.YahooBC-Most Active StocksThe body lists the most active stocks on the Nasdaq, NYSE, and NYSE American, showing volume, high, low, last price, and change for each. Curis Inc. leads with 116.7 million shares traded, while Tesla and Apple show large price changes. No additional context or analysis is provided.American Banking and Market NewsCuris (CRIS) Expected to Post Earnings on ThursdayCuris is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $2.29 per share and revenue of $1.00 million. The stock opened at $0.45, and analysts have an average rating of Hold with a target price of $43.00.TradingViewCuris Raises $8.5 Million in PIPE Offering; Sets Registration and Amends Prior WarrantsCuris announced a multi-part financing transaction anchored by an approximately $8.5 million gross PIPE offering of common stock or pre-funded warrants with accompanying warrants. The company also entered a registration rights agreement and amended prior warrants to reduce their exercise price to $0.60. Proceeds are intended to fund R&D and operations through initial CLL data expected in December 2026.Markets DailyReviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)Curis and Soligenix are compared on valuation, earnings, risk, and analyst ratings. Curis has higher revenue and earnings, a lower beta, and a stronger consensus rating with a $43 price target, beating Soligenix on 8 of 12 factors.TradingViewCuris, Inc. (CRIS) Prices $8.5M PIPE at $0.51; Cuts Warrant Strikes to $0.60Curis priced a private placement of 16.67M shares and warrants for about $8.5M at $0.51 per unit, with warrants at $0.60. The company repriced certain 2026 warrants to $0.60, and funds are expected to last through initial CLL data in Dec 2026.TradingViewCuris, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional InvestorsCuris, Inc. announced a $8.5 million private placement of 16,666,680 shares at $0.51 per share, with warrants and pre-funded warrants. Proceeds will fund research and development and working capital, expected to cover operations through initial CLL data in December 2026. The offering is expected to close on October 19, 2026.